martes, 2 de febrero de 2010

Metformin Extended Release Treatment of Adolescent Obesity


JOURNAL CLUB
Metformin Extended Release Treatment of Adolescent Obesity
A 48-Week Randomized, Double-Blind, Placebo-Controlled Trial With 48-Week Follow-up

Glaser Pediatric Research Network Obesity Study Group
Arch Pediatr Adolesc Med. 2010;164(2):116-123.

Background Metformin has been proffered as a therapy for adolescent obesity, although long-term controlled studies have not been reported.

Objective To test the hypothesis that 48 weeks of daily metformin hydrochloride extended release (XR) therapy will reduce body mass index (BMI) in obese adolescents, as compared with placebo.

Design Multicenter, randomized, double-blind, placebo-controlled clinical trial.

Setting The 6 centers of the Glaser Pediatric Research Network from October 2003 to August 2007.

Participants Obese (BMI95th percentile) adolescents (aged 13-18 years) were randomly assigned to the intervention (n = 39) or placebo groups.

Intervention Following a 1-month run-in period, subjects following a lifestyle intervention program were randomized 1:1 to 48 weeks' treatment with metformin hydrochloride XR, 2000 mg once daily, or an identical placebo. Subjects were monitored for an additional 48 weeks.

Main Outcome Measure Change in BMI, adjusted for site, sex, race, ethnicity, and age and metformin vs placebo.

Results After 48 weeks, mean (SE) adjusted BMI increased 0.2 (0.5) in the placebo group and decreased 0.9 (0.5) in the metformin XR group (P = .03). This difference persisted for 12 to 24 weeks after cessation of treatment. No significant effects of metformin on body composition, abdominal fat, or insulin indices were observed.

Conclusion Metformin XR caused a small but statistically significant decrease in BMI when added to a lifestyle intervention program.

Trial Registration clinicaltrials.gov Identifiers: NCT00209482 and NCT00120146


Author Affiliations: Authors: Darrell M. Wilson, MD (chair); Stephanie H. Abrams, MD; Tandy Aye, MD; Phillip D. K. Lee, MD; Carine Lenders, MD, MS, ScD; Robert H. Lustig, MD; Stavroula V. Osganian, MD, ScD; Henry A. Feldman, PhD.

open here:
http://archpedi.ama-assn.org/cgi/content/short/164/2/116?home

RELATED ARTICLE

This Month in Archives of Pediatrics & Adolescent Medicine
Arch Pediatr Adolesc Med. 2010;164(2):114.
FULL TEXT
http://archpedi.ama-assn.org/cgi/content/full/164/2/114

lunes, 1 de febrero de 2010

CDC - Seasonal Influenza (Flu) - 2009-10 Influenza (Flu) Season


2009-10 Influenza (Flu) Season
Questions & Answers about the 2009–2010 Flu Season


What has this flu season been like?
Flu seasons are unpredictable in a number of ways, including when they begin, how severe they are, how long they last and which viruses will spread. There were more uncertainties than usual going into this flu season (2009-2010), because of the emergence of the 2009 H1N1 influenza virus (previously called "novel H1N1" or "swine flu"). This virus caused the first influenza pandemic (global outbreak of disease) in more than 40 years.

The United States experienced its first wave of 2009 H1N1 pandemic activity in the spring of 2009, followed by a second wave of 2009 H1N1 activity in the fall. The 2009-2010 flu season began very early, with 2009 H1N1 viruses predominating and causing high levels of flu activity much earlier in the year than during most regular flu seasons. In addition, the fall wave of 2009 H1N1 activity (like the spring) was relatively more severe among people younger than 65 than seasonal flu usually is and relatively less severe among people older than 65 than seasonal flu usually is. Activity so far this season peaked in October and then declined quickly to below baseline levels in January. The early rise in flu activity in October is in contrast to past influenza seasons. Influenza activity usually peaks in January, February or March. (See graph of peak influenza activity by month in the United States from 1976-2009.)

There are still uncertainties surrounding the rest of this flu season, including the possibility of the circulation of seasonal influenza viruses and ongoing circulation of 2009 H1N1 viruses. In past pandemics, flu activity has occurred in waves and it’s possible that the United States could experience another wave of flu activity. In addition, sporadic cases of influenza may also be detected in the summer.

When did the flu season peak?
The weekly percentage of outpatient visits for influenza-like illness (ILI) peaked at the end of October at 7.7%, a level higher than the three previous influenza seasons, as reported by the U.S. Outpatient ILI Surveillance Network (ILINet). This percentage decreased to 1.8% at the beginning of January, 2010 The number of states reporting widespread influenza activity dropped from 49 at the end of October to zero at the beginning of January 2010. While states are not reporting widespread influenza, most states are still reporting some influenza activity.

Is the flu season over?
Although influenza activity has declined recently, additional waves of influenza activity due to 2009 H1N1, seasonal influenza viruses, or both, may occur later this influenza season. Flu season can last as late as May. Even if the U.S. doesn't experience a sharp increase in influenza activity during the remaining winter or spring (another "wave" of influenza), continued low level circulation of influenza viruses may continue during this time.

How is severity characterized?
The overall health impact (e.g., infections, hospitalizations and deaths) of a flu season varies from year to year. Based on available data from U.S. influenza surveillance systems monitored and reported by CDC, the severity of a flu season can be judged according to a variety of criteria, including:

The number and proportion of flu laboratory tests that are positive;
The proportion of visits to physicians for flu-like illness;
The proportion of all deaths that are caused by pneumonia and flu;
The number of flu-associated deaths among children; and
The flu-associated hospitalization rate among children and adults.
A season's severity is determined by assessing several of these measures and by comparing them with previous seasons.

How effective is the seasonal flu vaccine?
The effectiveness of flu vaccines can vary and depends in part on the match between the viruses in the vaccine and the flu viruses that are circulating in the community. If these are closely matched, vaccine effectiveness (VE) is higher. If they are not closely matched, VE can be reduced. During well-matched years, clinical trials have shown VE between 70% and 90% among healthy adults. For more information about seasonal flu vaccine effectiveness, visit "How Well Does the Seasonal Flu Vaccine Work?"

abrir aquí para acceder al documento CDC completo del cual se reproduce una mínima parte:
CDC - Seasonal Influenza (Flu) - 2009-10 Influenza (Flu) Season

Outbreaks of 2009 Pandemic Influenza A (H1N1) Among Long-Term--Care Facility Residents --- Three States, 2009



Outbreaks of 2009 Pandemic Influenza A (H1N1) Among Long-Term--Care Facility Residents --- Three States, 2009
Weekly
January 29, 2010 / 59(03);74-77


Hospitalization and death from seasonal influenza are more common among older adults and in long-term--care facilities (LTCFs) (1). Early data from the 2009 pandemic influenza A (H1N1) outbreak indicated that attack rates among persons aged ≥65 years were lower than in other age groups, and anti-influenza A antibodies that cross-react with 2009 H1N1 could be detected in up to one third of healthy adults aged >60 years (2). Based on these early data and anticipation of limited initial supplies of 2009 H1N1 vaccine, the Advisory Committee on Immunization Practices (ACIP) identified priority groups for vaccination (3), which did not include persons aged ≥65 years who did not have higher risk for influenza or its complications (3). During October and November 2009, CDC received reports of 2009 H1N1 outbreaks in LTCFs in Colorado, Maine, and New York. This report summarizes the three outbreaks, which involved facilities primarily housing older patients. These outbreaks illustrate that, despite the lower risk for infection with 2009 H1N1 among persons aged ≥65 years compared with seasonal influenza, 2009 H1N1 outbreaks still can occur in LTCFs. These outbreaks also underscore the importance of respiratory illness surveillance and recommended infection-control procedures in LTCFs. All health-care personnel should be vaccinated against seasonal influenza and 2009 H1N1. LTCF residents should receive seasonal influenza vaccination, and should be vaccinated against 2009 H1N1 after assessment of vaccine availability at the local level indicates that demand for vaccine among younger age groups is being met (3).

Outbreak Reports

Colorado. Beginning on October 14, 2009, the Colorado Department of Public Health and Environment assisted with the control of an outbreak of influenza-like illness (ILI)* in a 39-bed LTCF. During October 12--14, 2009, 11 residents (age range: 76--106 years) developed ILI (resident attack rate = 28%). Among the 11 residents, four tested positive by rapid influenza diagnostic test (RIDT), and three of these were positive by real-time reverse transcription--polymerase chain reaction (rRT-PCR) for 2009 H1N1. All of the ill residents lived in the same care unit. One of the 11 residents was hospitalized because of his ILI symptoms; no deaths occurred. Among 25 staff members at the facility, 10 reported experiencing ILI (staff attack rate = 40%); one worked while ill on October 10, which was 2 days before the onset of ILI in residents. Interventions implemented by the facility on October 14 included use of droplet precautions (4) and oseltamivir treatment for all residents with ILI, oseltamivir prophylaxis for all other residents and all staff members, restriction of exposed residents to their care unit, ill visitor restriction, and vaccination of staff members with 2009 H1N1 vaccine. Seasonal influenza vaccine had been offered to all residents and staff members before the outbreak, but 2009 H1N1 vaccine was not available at that time. No new ILI cases occurred after October 14.

Maine. On November 12, 2009, the Maine Center for Disease Control and Prevention conducted an investigation of a 2009 H1N1--related death in a patient from a 125-bed LTCF with 175 staff members. The patient was an ambulatory man aged 72 years who became ill on November 9, 2009, and died on November 10 of respiratory failure; 2009 H1N1 infection was confirmed by rRT-PCR. Absenteeism among health-care personnel at the facility had increased from a baseline average of two employee absences per day to seven employee absences per day in the week before the patient's illness, and to 11 employee absences per day the week of the patient's illness onset; eight staff members reported ILI symptoms (staff attack rate = 5%). No residents or staff members had been vaccinated for 2009 H1N1 or seasonal influenza. Because of concerns that more influenza infections might develop among residents, on November 13 the facility was closed to new admissions and visitors. Hand hygiene and cough etiquette were reinforced, droplet precautions were instituted for the care of infected residents, ill staff members were excluded from work, resident movement among the three wings of the facility was restricted, and oseltamivir prophylaxis was offered to all residents and staff members. All 125 residents and 159 of 175 staff members (91%) accepted the 2-week prophylaxis regimen. Six other residents (aged 72--89 years) developed ILI and were tested during November 13--17 (resident attack rate = 6%); two of these residents tested positive for 2009 H1N1 infection by rRT-PCR. Vaccination for 2009 H1N1 was not administered. No additional persons with ILI were identified after November 17.

New York. Starting on October 28, 2009, the New York State Department of Health (NYSDOH) assisted a 368-bed LTCF that had an outbreak of ILI among residents and staff members. From October 26 through November 6, a total of 41 of 368 residents (resident attack rate = 11%) and 135 of 615 staff members (staff attack rate = 22%) developed ILI. The first resident became ill on October 27. Ill residents were aged 66--96 years; none were hospitalized, and none died. A phlebotomist with onset of ILI on October 26 had worked on that day, drawing blood from 39 residents on all nine units in the facility. A nasopharyngeal swab collected from the phlebotomist tested positive for influenza A by RIDT and was later confirmed by rRT-PCR to be 2009 H1N1. Nasopharyngeal swabs were collected from six ill residents; one tested positive for 2009 H1N1 by rRT-PCR, and one tested positive for influenza A by culture.

Beginning on October 26, oseltamivir treatment was prescribed for all ill residents, and oseltamivir prophylaxis was offered to all unaffected residents and staff members. Enhanced surveillance for ILI was implemented, including contacting all absent employees to identify the reason for their absence. Staff members and visitors received education on standard precautions and droplet precautions and were excluded from the facility if ill. Children aged <12 years were restricted from visiting, and hand hygiene stations were placed outside of each unit. Ill residents were placed on droplet precautions. All residents and approximately 68% of staff members had been vaccinated for seasonal influenza at the time of the outbreak. No additional cases were reported after November 6. The facility offered 2009 H1N1 vaccine to all staff members on November 9.

Reported by
W Bamberg, MD, Colorado Dept of Public Health and Environment. N Finkner, MT, Arkansas Valley Regional Medical Center; D Guppy, Maine Center for Disease Control and Prevention, Univ of Southern Maine. D Simmerly, E Clement, MSN, S Kogut, MPH, J K Schaffzin, MD, PhD, New York State Dept of Health; A Fiore, MD, Influenza Div, National Center for Immunization and Respiratory Diseases; A Srinivasan, MD, N Stone, MD, A Kallen, MD, National Center for Preparedness, Detection, and Control of Infectious Diseases; S Hocevar, MD, EIS officer, CDC.

Editorial Note
This report describes three outbreaks of 2009 H1N1 infection in LTCFs. Anecdotal reports to CDC have indicated that these are not the only outbreaks of 2009 H1N1 in LTCFs that have occurred since the beginning of the pandemic; however, data on the incidence of influenza in LTCFs are not collected systematically at the national level. When the outbreak in Colorado was reported to CDC on October 21, 2009, CDC and the state of Colorado informally solicited reports of other outbreaks in LTCFs during a weekly Council of State and Territorial Epidemiologists teleconference. New York and Maine responded with information about similar outbreaks described in this report.

Several states conduct regular surveillance of outbreaks (including influenza) in LTCFs, and this information is shared with CDC. For example, by October 30, 2009, New York had identified a large number of 2009 H1N1 outbreaks in such facilities. The NYSDOH has required reporting of influenza and respiratory illness† from LTCFs since the late 1990s. In New York, from September 1 through December 15, 2009, reports of LTCFs with laboratory-confirmed influenza outbreaks increased by approximately tenfold to 50 (peak week was 17), compared with the same period during the 4 previous years (average: 5; range: 4--6 outbreaks). This increase early in the influenza season might reflect high levels of 2009 H1N1 circulating earlier in 2009 compared with past seasons when influenza activity typically peaked in January, February, or March (the average number of outbreaks for the peak week during the past three seasons has been 24). CDC has not solicited further LTCF outbreak reports since November 2009 and has not received additional reports since that time.

Seasonal influenza attack rates among residents of LTCFs have varied widely. The rates have ranged from 20% to 30% in more recent studies, but were as high as 70% in earlier studies (4). The 2009 H1N1 influenza outbreaks described in this report generally had lower resident attack rates (6% to 28%) and limited numbers of severe cases; however, because this was a convenience sample of facilities with outbreaks of 2009 H1N1 influenza where antiviral medications were started early in the outbreak, these examples might not be representative of other 2009 H1N1 influenza outbreaks.

All three outbreaks ended after initiation or reinforcement of recommended infection control practices (6,7) (Box). Although the extent to which measures used in these three outbreaks stopped transmission is uncertain, previous studies have found that use of antivirals with other control measures have effectively halted similar outbreaks. Likewise, the way in which influenza virus was introduced into these LTCFs is unknown. Influenza virus often is introduced into LTCFs via ill health-care personnel or visitors. In two of these outbreaks, ill health-care personnel worked while ill and might have served as a source of infection for at least some of the symptomatic residents. The possibility that transmission occurred between health-care personnel and patients underscores the importance of excluding ill health-care personnel from work and providing immunization with 2009 H1N1 vaccine to all LTCF staff members.

On April 26, 2009 (updated October 14, 2009), CDC released guidelines for general 2009 H1N1 infection-control recommendations for all health-care facilities, including LTCFs§. LTCFs should have surveillance in place to recognize respiratory illness outbreaks early, mechanisms to implement control measures, and the ability to collect and test respiratory specimens for influenza (7).

Vaccination of health-care personnel has been associated with lower rates of health-care--related seasonal influenza (8,9). Immunization of health-care personnel in LTCFs also has been linked to significant reductions in all-cause patient mortality (from 17% to 10%) and ILI (8). Health-care personnel in LTCFs are a priority group for 2009 H1N1 vaccination.

The use of antivirals for treatment and chemoprophylaxis of influenza in LTCFs has been recommended for seasonal influenza (6). In general, antiviral chemoprophylaxis for influenza is recommended for at least 2 weeks, and as long as 1 week after the last resident case has occurred (6). Oseltamivir or zanamivir also should be used for chemoprophylaxis during recognized outbreaks of 2009 H1N1 in LTCFs. In addition, LTCF residents who develop an illness suspected to be 2009 H1N1 should receive empiric treatment with either oseltamivir or zanamivir (10). Rapid influenza diagnostic testing should not be used to exclude the diagnosis of influenza because these tests have low sensitivity, and negative results on testing of persons with ILI should be followed up with rRT-PCR testing (7,10).

Acknowledgments
This report is based, in part, on contributions by M Miller, MS, Otero County Health Dept; A Pelletier, MD, B Bernier, MS, MPH, Maine Center for Disease Control and Prevention; and C Elliott, nursing home A, DJ Operario, PhD, M Fuschino, MS, and K St. George, PhD, New York State Dept of Health.

References
Gaillat J, Chidiac C, Fagnani F, et al. Morbidity and mortality associated with influenza exposure in long-term care facilities for dependent elderly people. Eur J Clin Microbiol Infect Dis 2009;28:1077--86.
Echevarría-Zuno,S, Mejía-Aranguré JM, Mar-Obeso JA, et. al. Infection and death from influenza A H1N1 virus in Mexico: a retrospective analysis. Lancet 2009;374:2072--9.
CDC. Use of influenza A (H1N1) 2009 monovalent vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR 2009;58(No. RR-10).
Siegel JD, Rhinehart E, Jackson M, Chiarello L; Healthcare Infection Control Practices Advisory Committee. 2007 Guideline for isolation precautions: preventing transmission of infectious agents in healthcare settings. Available at http://www.cdc.gov/ncidod/dhqp/pdf/guidelines/isolation2007.pdf . Accessed January 25, 2010.
Smith PW, Bennett G, Bradley S, et. al. SHEA/APIC guideline: infection prevention and control in the long-term care facility. Infect Control Hosp Epidemiol 2008;29:785--814.
CDC. Infection control measures for preventing and controlling influenza transmission in long-term care facilities; December 2008. Available at http://www.cdc.gov/flu/professionals/infectioncontrol/longtermcare.htm. Accessed January 25, 2010.
CDC. Interim recommendations for clinical use of influenza diagnostic tests during the 2009--10 influenza season; September 2009. Available at http://www.cdc.gov/h1n1flu/guidance/diagnostic_tests.htm. Accessed January 25, 2010.
CDC. Influenza vaccination of health-care personnel. MMWR 2006;55(No. RR-2).
Carman WF, Elder AG, Wallace LA, et al. Effects of influenza vaccination of health-care workers on mortality of elderly people in long-term care: a randomised controlled trial. Lancet 2000;355(9198):93--7.
CDC. Updated interim recommendations for the use of antiviral medications in the treatment and prevention of influenza for the 2009--2010 season; December 2009. Available at http://www.cdc.gov/h1n1flu/recommendations.htm. Accessed January 25, 2010.
* In all three outbreaks, ILI was defined as presence of fever with cough or sore throat.

† A sudden increase of acute febrile respiratory illness cases over the normal background rate or when any resident tests positive for influenza. One case of confirmed influenza by any testing method in a long-term--care facility resident is considered an outbreak.

§ Available at http://www.cdc.gov/h1n1flu/guidelines_infection_control.htm.

abrir aquí:
Outbreaks of 2009 Pandemic Influenza A (H1N1) Among Long-Term--Care Facility Residents --- Three States, 2009

Food and Drug Administration today approved Tykerb (lapatinib) in combination with Femara (letrozole)



Drug Information Update: FDA Expands Use of Approved Breast Cancer Drug

The Division of Drug Information (DDI) is CDER's focal point for public inquiries. We serve the public by providing information on human drug products and drug product regulation by FDA.

The U.S. Food and Drug Administration today approved Tykerb (lapatinib) in combination with Femara (letrozole) to treat hormone positive and HER2-positive advanced breast cancer in postmenopausal women for whom hormonal therapy is indicated.
HER2 is a protein involved in normal cell growth. It is found on some types of cancer cells, including breast cancer cells. In hormone positive breast cancer, the presence of certain hormones contributes to breast cancer growth. In HER2-positive breast cancer, stimulation of the HER2 receptor contributes to cancer cell growth. Breast cancer is the second leading cause of death among women. More than 192,000 women will be diagnosed with breast cancer this year.
For more information please visit: Tykerb


For Immediate Release: Jan. 29, 2010
Media Inquiries: Erica Jefferson, 301-796-4988, erica.jefferson@fda.hhs.gov
Consumer Inquiries: 888-INFO-FDA

FDA Expands Use of Approved Breast Cancer Drug
Provides oral regime for hormone positive and HER2-positive advanced breast cancer


The U.S. Food and Drug Administration today approved Tykerb (lapatinib) in combination with Femara (letrozole) to treat hormone positive and HER2-positive advanced breast cancer in postmenopausal women for whom hormonal therapy is indicated.

HER2 is a protein involved in normal cell growth. It is found on some types of cancer cells, including breast cancer cells. In hormone positive breast cancer, the presence of certain hormones contributes to breast cancer growth. In HER2-positive breast cancer, stimulation of the HER2 receptor contributes to cancer cell growth. Breast cancer is the second leading cause of death among women. More than 192,000 women will be diagnosed with breast cancer this year.

“This drug combination of Tykerb plus Femara provides women being treated for advanced breast cancer with an important treatment option. This entirely oral treatment regimen works by targeting both HER2 and the hormone receptors, thereby slowing the cancer cells’ ability to grow or spread,” said Richard Pazdur, M.D., director of the Office of Oncology Drug Products, in the FDA’s Center for Drug Evaluation and Research.

Women with HER2-positive disease receiving the Tykerb plus Femara combination more than doubled the time they lived without the cancer progressing compared with those receiving Femara alone (35 weeks vs. 13 weeks). Women in the company sponsored study were randomized to receive Tykerb plus Femara or Femara alone. It is too early to determine whether an improvement in overall survival will be observed in the clinical trial.

Tykerb works by depriving tumor cells of signals needed to grow. Tykerb enters the cell and blocks the function of the HER2 protein.

Tykerb was initially approved in combination with a chemotherapy drug, Xeloda (capecitabine) in 2007. This combination was used to treat women with advanced breast cancer tumors with the HER2 protein who had received prior treatment with chemotherapy drugs, including an anthracycline and a taxane, and Herceptin (trastuzumab), an anti-cancer antibody used to treat HER2-positive advanced breast cancer.

Safety information from this study was consistent with previous Tykerb clinical studies in advanced breast cancer. The most commonly reported side effects of the combination were diarrhea, rash, nausea and fatigue. Treatment with Tykerb also has been associated with decreases in heart function, liver damage, and lung tissue inflammation. Fetal harm may occur if used to treat advanced breast cancer in pregnant women. Patients should talk to their health care provider about the potential side effects, drug interactions, and other medical conditions.

Tykerb is marketed by Collegeville, Pa.-based GlaxoSmithKline.
Femara is marketed by Lebanon, Pa.-based Novartis AG.

For more information:
FDA Office of Oncology Drug Products
http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm091745.htm

National Cancer Institute – Breast Cancer
http://www.cancer.gov/cancertopics/types/breast

II Curso Universitario de Educación Médica Continua en Geriatría





II Curso Universitario de Educación Médica Continua en Geriatría
Instituto Universitario del Hospital Italiano de Buenos Aires


El día 16 de Abril del 2010 comienza el II Curso Universitario de Educación Médica Continua en Geriatría. Los médicos nos vemos en la necesidad de mantenernos actualizados dada la gran cantidad de información médica que se presenta a diario. La geriatría no es la excepción. Cada vez son mas los pacientes mayores de 65 años que atendemos y cada vez es mas necesario estar al día con los conocimientos.

Este curso, netamente práctico, pretende tener un enfoque diferente, de suma utilidad para todos aquellos que estamos habituados a atender pacientes ancianos, y queremos mantenernos actualizados.

Esta estructurado con un formato ideal para aquellos que por razones de accesibilidad o tiempo no pueden realizar cursos habitualmente. El enfoque práctico y de actualidad hace que este curso sea renovado permanentemente y sea de utilidad a modo de actualización permanente.

Prestigioso cuerpo docente:

· Dr. Luis Cámera
· Dr. Javier Benchimol
· Dra. Claudia Alonzo
· Dr. Pablo Bongiorno
· Dr. Eduardo Stonski
· Dr. Esteban de la Torre
· Dr. Fernando Morano
· Dra. Fabiana Giber
· Dra. Sandra Aronson
· Dra. Mercedes Mattiussi
· Dr. Marcelo Schapira
· Dr. Ruben Vallejos
· Dr. Daniel Weissbrod
· Dra. Griselda Gomez
· Dra. Maria Elena Guajardo
· Dra. Mariela González Salvia
· Dra. Belén Outumuro
· Dr. Miguel Sassno
· Dr. Daniel Seinhart
· Dr. Eduardo Stonski
· Dra. María Elvira Soderlund
· Dra. Laura Brescacín



Temario:

· Evaluación Funcional Global del Anciano. El paciente vulnerable
· Fisiología y Fisiopatología del endotelio, mediadores químicos.
· Intervenciones sobre el curso de la enfermedad
· CIGA Neurología
· Queja Cognitiva, evaluación y manejo práctico
· Síndrome Confusional, clínica y tratamiento actual
· Valoración nutricional del adulto mayor: diagnósticos enfoques terapéuticos.
· Pérdida de peso involuntaria en el adulto mayor: algoritmo diagnóstico y manejo.
· CIGA Gastroenterología
· Evaluación de la Depresión y manejo de antidepresivos por el médico de cabecera Trastorno de ansiedad, evaluación y manejo práctico
· Fiebre de origen desconocido en el anciano: causas, evaluación y tratamiento.
· Trastorno de la marcha y caídas, por donde empezar?
· Trastornos del sueño. Insomnio. Que hacer?
· Aplastamiento vertebral agudo osteoporótico: evaluación y tratamiento
· Manejo del dolor en el anciano.
· CIGA Clásico
· Incontinencia de orina
· Desde la queja al tratamiento.
· Inmovilidad y sus consecuencias. Escaras. Como prevenirlas. Como tratarlas.
· Fractura de cadera: Epidemiología, tipos, enfoques terapéuticos.
· Internación domiciliaria en fractura de cadera



DIRECTORES:
Dres. Miguel A. Sassano y Ruben Vallejos

COORDINADOR DOCENTE:
Dres. Sandra Aronson y Pablo Bongiorno

FECHA DE REALIZACIÓN:
Comienza 16 de Abril de 2010
Finaliza 19 de Noviembre de 2010

DÍAS Y HORARIO DE CURSADA:
Terceros días viernes de cada mes de 9.00 a 18:00 hs.

DESARROLLO: 132 horas docentes
Clases Teóricas y Prácticas
Incluye Horas Presenciales, Lectura Critica de Trabajos, participación en trabajos prácticos y acceso a clases y bibliografía por medio del Campus virtual del Hosp. Italiano
Certificado con validez para cubrir horas de actualización que exige el GCBA

DIRIGIDO A:
Medicina Interna, Geriatría,
Medicina Familiar, Psiquiatría,
Clínica Médica, Generalistas y a
especialidades relacionadas que atiendan
pacientes mayores de 65 años

INSCRIPCIÓN:
Instituto Universitario del Hospital Italiano de Buenos Aires
Potosí 4249 - Buenos Aires - Argentina
Tel.4959-0200 interno 5324

LUGAR DE REALIZACIÓN:
Asociación Mutual de Profesionales del Hospital Italiano
Potosí 4296 – CABA

ORGANIZA Y CERTIFICA:
Instituto Universitario del Hospital Italiano de Buenos Aires
Programa de Medicina Geriátrica
Servicio de Clínica Médica

CO-ORGANIZA:
Sociendad Argentina de Medicina

ARANCEL:

Contado - Pesos Pago en Cuotas - Pesos
(Matricula + Cuotas)
Profesionales $ 1600$1900 (500 +7x$200)
Residentes/Becarios $ 1300$1500 (100+ 7x$200)
Grupos de Profesionales (+3)
Socios SAM - Socios SAGG $ 1450$1700 (300+ 7x$200)
Médicos y Profesionales del
Hospital Italiano de BA $ 850$950 ( 250+ 7x$100)

Incluye inscripción y certificado de los tres CIGA, coffee break, lunch y material
docente. Acceso al Campus Virtual

INFORMES E INSCRIPCIÓN:
Sociedad Argentina de Medicina
Tel.4864-3622
Servicio de Clínica Médica del Hospital Italiano
Tel.4959-0200 interno 9887

VACANTES LIMITADAS
INSCRIPCION VIA WEB
Sitio: www.cursoshiba.com.ar
Mail : info@cursoshiba.com.ar

II Curso Universitario de Educación Médica Continua en Geriatría

MENINGOCOCCEMIA - ISID / REPÚBLICA DOMINICANA y HAITÍ


MENINGOCOCCEMIA, MUERTE DE VOLUNTARIO - R. DOMINICANA EX: HAITÍ

Un comunicado de ProMED-mail
http://www.promedmail.org
ProMED-mail es un programa de la Sociedad Internacional de Enfermedades Infecciosas
http://www.isid.org

Fecha: 31 de enero, 2010
Fuente: El Diario, Nueva York, EEUU
http://www.impre.com/eldiariony/noticias/nuestros-paises/2010/2/1/bacteria-mata-a-pastor-evangel-171172-1.html [Editado por J. Torres]

El Ministerio de Salud Pública mantiene bajo vigilancia médica a varias personas del entorno de un pastor evangélico que falleció la madrugada del sábado a causa de meningococemia, luego de contagiarse en Haití, a donde acudió para ayudar a las víctimas del terremoto.

Bautista Rojas Gómez aseguró que son sometidas a las debidas medidas de profilaxis las personas que tuvieron contacto con el pastor Juan Sánchez, de 63 años de edad, quien acudió a Puerto Príncipe con otros 12 miembros del concilio Iglesia de Dios de la Profecía, de Villa Faro, en la parte oriental de esta capital.

Sánchez estuvo en el vecino país una semana, desde el día 21 hasta el jueves 28. Su congregación trabajó en la instalación de un albergue provisional para niños de un orfanato que fue destruido por el terremoto. El religioso falleció luego de estar varios días ingresado en el Centro Médico UCE, de esta capital.

"Localizamos el lugar de donde proceden (los evangélicos), el lugar donde estuvo (Sánchez) en Puerto Príncipe, sus contactos aquí y los que tuvo allá, a los fines de iniciar las medidas de profilaxis, vigilancia de esas personas y darle la quimioprofilaxis que se da en esos casos", dijo el ministro de Salud, Rojas Gómez.

El funcionario aseguró que el Gobierno trabaja en la prevención de enfermedades como la Meningococemia, una infección del torrente sanguíneo causada por la bacteria _Neisseria meningitidis_ que con frecuencia se aloja en las vías respiratoria.

Rojas Gómez sostuvo que Salud Pública mantiene la vigilancia epidemiológica tras la ocurrencia del terremoto. Informó además que a los haitianos que cruzan la frontera se le aplica tratamiento preventivo contra la malaria y se les inyecta contra enfermedades como el tétanos. Sin embargo, los inmigrantes ilegales no pasan por los
puestos regulares de migración para evadir a las autoridades.

Ni el pastor Sánchez fallecido ni sus compañeros de congregación fueron vacunaron al penetrar a territorio haitiano, pese al control sanitario que dice mantener Salud Pública. Comunicado por: Jaime R. Torres [torresjaime@cantv.net]
-- ProMED-ESP
...jt
*#######################*
ProMED-mail hace el máximo esfuerzo posible para verificar los informes que incluimos en nuestros envíos, pero no garantiza la exactitud ni integridad de la información, ni de cualquier aseveración u opinión basadas en ella. El lector debe asumir todos los riesgos incurridos al utilizar la información incluida o archivada por ProMED-mail. La Sociedad Internacional de Enfermedades Infecciosas (International Society for Infectious Diseases, ISID) y los proveedores de servicio asociados a ella no serán responsables por errores u omisiones, ni sujetos a acción legal por daños o perjuicios incurridos como resultado del uso o confianza depositados en el material
comunicado o archivado por ProMED-mail.
*************************

IV Curso Universitario de Clínica y Tratamiento de la DEMENCIA





IV Curso Universitario de Clínica y Tratamiento de la DEMENCIA
Instituto Universitario del Hospital Italiano de Buenos Aires


El día 04 de mayo del 2010 comienza el IV Curso Universitario integral, extenso y multidisciplinario de Clínica y Tratamiento de la DEMENCIA

Con el propósito de brindar formación de postgrado en el área de las Demencias, y el objetivo de formar expertos en evaluación y tratamiento de dicha patología, y con una visión multidisciplinaria, hemos desarrollado este curso, que ha través de contenidos teóricos y prácticos, dictados por reconocidos docentes y expertos, brindará a los alumnos las competencias, destrezas y habilidades para el manejo integral de las Demencias.

Esta necesidad se fundamenta en el fenómeno del envejecimiento poblacional, que provoca profundos impactos en los sistemas de Salud, donde los problemas relacionados con las alteraciones cognitivas, conductuales y la disminución de la funcionalidad, son que provocan el mayor reto para la medicina actual, con la paradoja de haber una escasa oferta de cursos formativos para los profesionales que deben enfrentares a diario con esta problemática.

Con una estructura de clases teóricas, quincenales, y discusión del tema dictado por reconocidos expertos, se complementa con prácticos de evaluación a pacientes en conjunto con tutores/capacitadores, que brindarán al alumno todas las herramientas de valoración de las funciones mentales superiores, la funcionalidad y la evaluación conductual.


Temas a Desarrollar:

· Concepto e historia de Demencia
· Memoria y envejecimiento
· Demencias: prevalencias, incidencias factores de riesgo y protección asociados con la edad temprana
· Demencia: morbimortalidad, valoración de sesgos de selección
· La entrevista clínica estructurada
· Neuroanatomía normal en ancianos y en demencias
· Neurofisiología y neurobiología del envejecimiento
· Valor del Screening en pacientes dementes
· Semiología y trastorno de la memoria
· Semiología de trastornos conductuales
· Test de evaluación neuropsicológica
· Evaluación de memorias, funciones ejecutivas, lenguaje y praxias
· Test de evaluación conductual y depresión
· Evaluación funcional en las demencias, estadios y pronósticos
· Baterías neuropsicológicas complejas
· Valoración nutricional en demencia
· Laboratorio en demencia. Neuroimágenes
· Enfermedad de Alzheimer, daño cognitivo leve
· Evaluación clínica y neuropsicológica de demencia vascular
· Demencia por cuerpos de Lewy, Demencia frontotemporal
· Delirium. Clínica y tratamiento
· Demencias en jóvenes
· Depresión y ansiedad en demencia
· Tratamientos de trastornos conductuales
· Tratamientos no farmacológicos y farmacológicos de las demencias
· El cuidador en la demencia, bioética y directivas anticipadas
· Dolor y Demencia
· Institucionalización del paciente demente

Prestigioso cuerpo docente:
Coordinadores Docentes

· Dra. María Elvira Soderlund
· Dra. Mariela González Salvia
· Dra. Mercedes Mattiussi
· Dr. Javier Benchimol
· Dra. Belen Outumuro
· Dra. Fabiana Giber
· Dr. Lucio Bellomo
· Dra. María Elena Guajardo
· Dra. Jimena Restibo


Docentes Invitados

· Dr. R. Arizaga
· Dra C. Besada
· Dr. G. Sevlever
· Dr. C. Mangone
· Dr. R. Allegri
· Dr. F. Manes
· Dr. Taragano
· Dr. A. Famulari
· Dr. J. Kremer
· Dr. D. Zuin
· Dr. I. Brusco
· Dr. P. Bagnatti
· Dr. J. Ollari
· Dr. A. Lychinski
· Dr. A. Golimstok
· Dr. C. Serrano
· Dr. G. Requejo
· Dr. D. Sarasola
· Dr. S. Christiansen
· Dr. P. Argibay
· Dr. D. Sarassola
· Dr. A. Cherro
· Dr. G. Reich
· Dr. F. Quaglia
· Dra. C. Serrano
· Lic. R. Gonzalezo
· Dra. V. Lerotich
· Lic. Edith Labos
· Lic. L. Pedace
· Dr. J. Funes
· Dr. O. Genovese
· Dr. J. Funes
· Lic. L. Policastro
· Lic. J. Camino
· Lic. M. Roca



DIRECCION:

Dres. Daniel Seinhart y Rubén Vallejos

DIRECTORES ASOCIADOS:

Dres. L Camera, D Matusevich, A Golimstok, M Sassano, M Schapira

FECHA DE REALIZACIÓN:

Mayo 4 a Diciembre 14 del 2010

DÍAS Y HORARIO DE CURSADA:

Teóricos: Martes de 17.15 a 21.00 Horas
Prácticos: Evaluaciones de pacientes 4 por mes

DESARROLLO: 256 horas docentes

Clases Teóricas y Prácticas (40% prácticos)
Campus Virtual y foro de discusión web
Discusión de bibliografía y casos clínicos
Evaluación final teórica y defensa de monografía

INFORMES E INSCRIPCIÓN:

Servicio de Clínica Médica del Hospital Italiano
Tel.4959-0200 interno 9887
Instituto Universitario del Hospital Italiano de Buenos Aires
Potosí 4249 - Buenos Aires - Argentina
Tel.4959-0200 int 5324

ORGANIZA Y CERTIFICA:

Instituto Universitario del Hospital Italiano de Buenos Aires
Programa de Medicina Geriátrica - P.M.G.
Servicio de Clínica Médica del Hospital Italiano de Buenos Aires

DIRIGIDO A:

Medicina Interna, Neurología, Medicina Familiar
Psiquiatría, Psicología, y otras especialidades
con interés en el Tratamiento de la Demencia

ARANCEL:

Contado - Pesos Pago en Cuotas - Pesos
(Matricula + Cuotas)
Profesionales $ 2700 $3500 ($700 + 7x$ 400)
Residentes/Becarios/No Médicos$ 1800 2500 ($400 + 7x$300)

Grupos de Profesionales (+3)
Socios SAM - Socios SAGG $ 2500$3200 ($400 + 7$400)

Grupos de residentes/Becarios/No Médicos$ 1600$2300 ($200 + 7x$300)

Médicos y Profesionales del
Hospital Italiano de BA $ 1350$1750 ($350 + 7x$200)



LUGAR DE REALIZACIÓN:

Instituto Universitario del Hospital Italiano de Buenos Aires
Potosí 4249 - Buenos Aires - Argentina

VACANTES LIMITADAS (35)
INSCRIPCIÓN VÍA WEB:

Sitio: www.cursoshiba.com.ar
Sitio: www.hospitalitaliano.org.ar
Mail : info@cursoshiba.com.ar

IV Curso Universitario de Clínica y Tratamiento de la DEMENCIA